Modeling acute graft-versus-host disease (aGVHD) in murine bone marrow transplantation (BMT) models with MHC disparity.
Scheurer J, Leithäuser F, Debatin KM, Strauss G.
Methods Cell Biol. 2022;168:19-39. doi: 10.1016/bs.mcb.2021.12.007. Epub 2022 Jan 10.
Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide.
Robinson TM, O'Donnell PV, Fuchs EJ, Luznik L.
Semin Hematol. 2016 Apr;53(2):90-7. doi: 10.1053/j.seminhematol.2016.01.005. Epub 2016 Jan 15.
Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide.
McCurdy SR, Kanakry CG, Tsai HL, Gojo I, Smith BD, Gladstone DE, Bolaños-Meade J, Borrello I, Matsui WH, Swinnen LJ, Huff CA, Brodsky RA, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L.
Biol Blood Marrow Transplant. 2019 Jun;25(6):1128-1135. doi: 10.1016/j.bbmt.2018.12.767. Epub 2018 Dec 30.
Hepatobiliary disease after bone marrow transplant.
Dezan MGF, Cavalcante LN, Cotrim HP, Lyra AC.
Expert Rev Gastroenterol Hepatol. 2023 Feb;17(2):129-143. doi: 10.1080/17474124.2023.2169671. Epub 2023 Feb 2.
Ambivalent role of FasL in murine acute graft-versus-host-disease.
Bernard-Bloch R, Lebrault E, Li X, Sutra Del Galy A, Garcia A, Doliger C, Parietti V, Legembre P, Socié G, Karray S.
J Leukoc Biol. 2023 Sep 1;114(3):205-211. doi: 10.1093/jleuko/qiad040.
Low diversity of gut microbiota in the early phase of post-bone marrow transplantation increases the risk of chronic graft-versus-host disease.
Konishi T, Kusakabe S, Hino A, Inamoto K, Yoshifuji K, Kiridoshi Y, Takeshita K, Sasajima S, Toya T, Igarashi A, Najima Y, Kobayashi T, Doki N, Motooka D, Nakamura S, Suyama M, Suda W, Shiota A, Atarashi K, Hattori M, Honda K, Yokota T, Ohashi K, Shibayama H, Fukushima K, Kakihana K.
Bone Marrow Transplant. 2021 Jul;56(7):1728-1731. doi: 10.1038/s41409-021-01249-2. Epub 2021 Mar 8.
Effect of graft-versus-host disease on outcomes of HLA-haploidentical peripheral blood transplantation using post-transplant cyclophophamide.
Shimomura Y, Komukai S, Kitamura T, Sobue T, Akahoshi Y, Kanda J, Ohigashi H, Nakamae H, Hiramoto N, Nagafuji K, Tanaka T, Eto T, Ota S, Maruyama Y, Akasaka T, Matsuoka KI, Mori Y, Fukuda T, Atsuta Y, Terakura S.
Bone Marrow Transplant. 2024 Jan;59(1):66-75. doi: 10.1038/s41409-023-02142-w. Epub 2023 Oct 28.
Management of graft-versus-host disease in paediatric bone marrow transplant recipients.
Zecca M, Locatelli F.
Paediatr Drugs. 2000 Jan-Feb;2(1):29-55. doi: 10.2165/00148581-200002010-00004.
Bone marrow transplantation for acquired aplastic anemia: What's new.
Bacigalupo A, Benintende G.
Best Pract Res Clin Haematol. 2021 Jun;34(2):101284. doi: 10.1016/j.beha.2021.101284. Epub 2021 Jul 7.
Influence of post-transplant mucosal-associated invariant T cell recovery on the development of acute graft-versus-host disease in allogeneic bone marrow transplantation.
Kawaguchi K, Umeda K, Hiejima E, Iwai A, Mikami M, Nodomi S, Saida S, Kato I, Hiramatsu H, Yasumi T, Nishikomori R, Kondo T, Takaori-Kondo A, Heike T, Adachi S.
Int J Hematol. 2018 Jul;108(1):66-75. doi: 10.1007/s12185-018-2442-2. Epub 2018 Mar 26.
